右美托咪定注射液用于重度颅脑损伤患者的临床研究  

Clinical trial of dexmedetomidine injection in the treatment of severe craniocerebral injury

作　　者：孙艳[1] 张娟[1] SUN Yan;ZHANG Juan(Department of Anesthesiology,First Affiliated Hospital of Suzhou University,Suzhou 251006,Jiangsu Province,China)

机构地区：[1]苏州大学附属第一医院麻醉科

出　　处：《中国临床药理学杂志》2019年第23期2957-2959,2974,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(81601666)

摘　　要：目的观察右美托咪定注射液用于重度颅脑损伤患者的临床疗效及安全性。方法将62例重度颅脑损伤患者随机分为对照组和试验组,每组31例。麻醉诱导前,对照组给予0.9%NaCl 1.0μg·kg^-1,10 min内泵入,之后以0.5μg·kg^-1·h^-1持续静脉泵注;试验组给予右美托咪定1.0μg·kg^-1,10 min内泵入,之后以0.5μg·kg^-1·h^-1持续静脉泵注。2组患者的麻醉诱导和麻醉维持方案均保持一致性。比较2组患者的脑代谢指标和药物不良反应的发生情况。结果麻醉诱导即刻,试验组和对照组的颈静脉血氧饱和度(SjvO2)分别为(68.28±8.09)%和(64.07±7.14)%,脑氧摄取率(CERO2)分别为(31.68±2.29)%和(35.16±2.34)%;插管后2 min,试验组和对照组的SjvO2分别为(72.06±6.19)%和(67.17±7.11)%,CERO2分别为(30.35±2.10)%和(33.31±2.40)%;术毕,试验组和对照组的SjvO2分别为(73.27±7.31)%和(68.28±8.13)%,CERO2分别为(30.11±1.94)%和(32.37±2.18)%。2组患者不同时间点的上述指标比较,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有低血压和心动过缓,对照组的药物不良反应主要有低血压和心动过缓。试验组和对照组的总药物不良反应发生率分别为16.13%和9.68%,差异无统计学意义(P>0.05)。结论右美托咪定注射液可以改善重度颅脑损伤麻醉术患者的脑代谢功能,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety ofdexmedetomidine injection in the treatment of severe craniocerebral injury.Methods A total of 62 patients with severe craniocerebral injury were randomly divided into control and treatment groups with 31 cases per group.Before anesthesia induction,control group was given 0.9%NaCl 1.0μg·kg^-1 by intravenous pump within 10 min,and then continuous intravenous infusion of 0.5μg·kg^-1·h^-1 was performed.Treatment group received dexmedetomidine 1.0μg·kg^-1 by intravenous pump within 10 min,and then continuous intravenous infusion of 0.5μg·kg^-1·h^-1 was performed.The anesthesia induction and maintenance schemes of the two groups were consistent.The levels of brain metabolism and adverse drug reactions were compared between two groups.Results Immediately after induction of anesthesia,oxygen saturation in jugular venous blood(SjvO2)of treatment and control groupswere(68.28±8.09)%and(64.07±7.14)%,cerebral extraction rateof oxygen(CERO2)were(31.68±2.29)%and(35.16±2.34)%.2 min after intubation,SjvO2 of treatment and control groups were(72.06±6.19)%and(67.17±7.11)%,CERO2 were(30.35±2.10)%and(33.31±2.40)%.End of operation,SjvO2 of treatment and control groups were(73.27±7.31)%and(68.28±8.13)%,CERO2 were(30.11±1.94)%and(32.37±2.18)%.There were significant differences in the above indexes at different time points between two groups(all P<0.05).The adverse drug reactions in the treatment group were hypotension and bradycardia,while those in the control group were hypotension and bradycardia.The total incidences of adverse drug reactions in the treatment and control groups were 16.13%and 9.68%without significant difference(P>0.05).Conclusion Dexmetomidine injection can improve the brain metabolic function of patients with severe craniocerebral injury and does not increase the incidence of adverse drug reactions.

关 键 词：右美托咪定注射液 重度颅脑损伤 安全性评价 

分 类 号：R971.2[医药卫生—药品]